son of T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (333)	12/19/1999 12:53:00 PM
From: Biotech Jim	Read Replies (1) of 673

I agree that both NBIX and GLIA are both still undervalued. If either of their Phase 2 study drugs (CRF1 antagonist for the former or the H3 antagonist - inverse agonist for the afficionado- for the latter) make it to the clinic, then each stock has the potential to rise 30-fold over the next 5 years. In the shorter term of 1 year, I'm looking for a 2 to 5-fold increase for each. Let's find the next ten baggers now! From my perch, I see that SEPR, VLTS and CBST all have the potential. We just need to continue to see steady progress in both the ongoing clinical studies as well as in new areas that correspond to their emerging projects. BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next